BHC

Over the past six months, Bausch Health's stock has experienced notable movements, with its share price at $5.65 as of September 17, 2026, reflecting an 18.00% decline over the past year. In August 2026, the stock surged approximately 26-27% following the announcement of strong second-quarter 2026 results and a raised 2026 outlook, where non-GAAP EPS and revenue both surpassed consensus estimates. This marked the 13th consecutive quarter of year-over-year revenue and adjusted EBITDA growth for BHC's core business, excluding Bausch + Lomb. Recent news from August-September 2026 includes the expansion of collaboration with YUN to Mexico and additional EMEA markets, the availability of Solta Medical's Fraxel FTX® in Australia, the announcement of 2026 Gastrointestinal Health Scholars Program Winners, an insider selling 36,827 shares in a plan trade, and CEO Thomas J. Appio's appointment to the Bausch + Lomb Board.